Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-07-2019 | NSCLC | Original Article

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

Authors: Hitesh B. Mistry, Gabriel Helmlinger, Nidal Al-Huniti, Karthick Vishwanathan, James Yates

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2019

Abstract

Purpose

Imaging time-series data routinely collected in clinical trials are predominantly explored for covariates as covariates for survival analysis to support decision-making in oncology drug development. The key objective of this study was to assess if insights regarding two relapse resistance modes, de-novo (treatment selects out a pre-existing resistant clone) or acquired (resistant clone develops during treatment), could be inferred from such data.

Methods

Individual lesion size time-series data were collected from ten Phase III study arms where patients were treated with either first-generation EGFR inhibitors (erlotinib or gefitinib) or chemotherapy (paclitaxel/carboplatin combination or docetaxel). The data for each arm of each study were analysed via a competing models framework to determine which of the two mathematical models of resistance, de-novo or acquired, best-described the data.

Results

Within the first-line setting (treatment naive patients), we found that the de-novo model best-described the gefitinib data, whereas, for paclitaxel/carboplatin, the acquired model was preferred. In patients pre-treated with paclitaxel/carboplatin, the acquired model was again preferred for docetaxel (chemotherapy), but for patients receiving gefitinib or erlotinib, both the acquired and de-novo models described the tumour size dynamics equally well. Furthermore, in all studies where a single model was preferred, we found a degree of correlation in the dynamics of lesions within a patient, suggesting that there is a degree of homogeneity in pharmacological response.

Conclusions

This analysis highlights that tumour size dynamics differ between different treatments and across lines of treatment. The analysis further suggests that these differences could be a manifestation of differing resistance mechanisms.

Available only for authorised users

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer Oxf Engl 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRef

Ribba B, Holford NH, Magni P et al (2014) A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacomet Sys Pharmacol 3:1–10

Hata AN, Niederst MJ, Archibald HL et al (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22:262–269. https://doi.org/10.1038/nm.4040 CrossRefPubMedPubMedCentral

Hede K (2013) Project data sphere to make cancer clinical trial data publicly available. J Natl Cancer Inst 105:1159–1160. https://doi.org/10.1093/jnci/djt232 CrossRefPubMed

Green AK, Reeder-Hayes KE, Corty RW et al (2015) The project data sphere initiative: accelerating cancer research by sharing data. Oncologist 20:464. https://doi.org/10.1634/theoncologist.2014-0431 CrossRefPubMedPubMedCentral

Guinney J, Wang T, Laajala TD et al (2017) Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol 18:132–142. https://doi.org/10.1016/S1470-2045(16)30560-5 CrossRefPubMed

Efron B (1979) Bootstrap Methods: another Look at the Jackknife. Ann Stat 7:1–26. https://doi.org/10.1214/aos/1176344552 CrossRef

Yule GU (1927) On a Method of Investigating Periodicities in Disturbed Series, with Special Reference to Wolfer’s Sunspot Numbers. Philos Trans R Soc Lond Ser Contain Pap Math Phys Character 226:267–298CrossRef

10.

R Development Core Team (2011) R: a language and environment for statistical computing. the R Foundation for Statistical Computing, Vienna

11.

(2000) Fitting linear mixed-effects models. In: Mixed-effects models in S and S-PLUS. Springer New York, pp 133–199

12.

Fukuoka M, Wu Y-L, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874. https://doi.org/10.1200/JCO.2010.33.4235 CrossRefPubMed

13.

Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062. https://doi.org/10.1200/JCO.2011.39.5848 CrossRefPubMed

14.

Douillard J-Y, Ostoros G, Cobo M et al (2014) First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 110:55–62. https://doi.org/10.1038/bjc.2013.721 CrossRefPubMed

15.

Natale RB, Thongprasert S, Greco FA et al (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer. J Clin Oncol 29:1059–1066. https://doi.org/10.1200/JCO.2010.28.5981 CrossRefPubMed

16.

Scagliotti GV, Krzakowski M, Szczesna A, et al. (2012) Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial. J Clin Oncol. https://doi.org/10.1200/JCO.2011.39.2993 CrossRefPubMed

17.

Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol 21:2237–2246. https://doi.org/10.1200/JCO.2003.10.038 CrossRefPubMed

18.

Kim ES, Hirsh V, Mok T, et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet Lond Engl 372:1809–1818. https://doi.org/10.1016/S0140-6736(08)61758-4 CrossRef

19.

Herbst RS, Sun Y, Eberhardt WEE, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619–626. https://doi.org/10.1016/S1470-2045(10)70132-7 CrossRefPubMedPubMedCentral

20.

Ramlau R, Gorbunova V, Ciuleanu TE, et al. (2012) Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30:3640–3647. https://doi.org/10.1200/JCO.2012.42.6932 CrossRefPubMed

21.

Burrell RA, Swanton C (2014) Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 8:1095–1111. https://doi.org/10.1016/j.molonc.2014.06.005 CrossRefPubMedPubMedCentral

22.

Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol Off J Am Soc Clin Oncol 4:244–257CrossRef

23.

Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108:479–485. https://doi.org/10.1038/bjc.2012.581 CrossRefPubMedPubMedCentral

24.

Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259–2265PubMed

25.

Chmielecki J, Foo J, Oxnard GR et al (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:9059. https://doi.org/10.1126/scitranslmed.3002356 CrossRef

26.

Moiseyenko FV, Moiseyenko VM, Aleksakhina SN et al (2016) Survival outcomes in EGFR mutation-positive lung cancer patients treated with gefitinib until or beyond progression. Oncol Res Treat 39:605–614. https://doi.org/10.1159/000449024 CrossRefPubMed

27.

Heindl A, Nawaz S, Yuan Y (2015) Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest 95:377–384. https://doi.org/10.1038/labinvest.2014.155 CrossRefPubMed

Title: Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
Authors: Hitesh B. Mistry
Gabriel Helmlinger
Nidal Al-Huniti
Karthick Vishwanathan
James Yates
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Erlotinib
Gefitinib
Cytostatic Therapy
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03840-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity

Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice

Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors

Stress resilience and survival among cancer patients: is there any absolute truth?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer